Cargando…

SS-5 Current management of primary central nervous system lymphoma

Primary CNS Lymphomas (PCNSLs) is a highly aggressive malignant tumor with poor prognosis and increasing incidence in elderly patients. High-dose methotrexate (HD-MTX) followed by whole-brain radiation therapy (WBRT) improves survival in PCNSLs. Several HD-MTX–based regimens, in combination with alk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mishima, Kazuhiko, Shirahata, Mitsuaki, Adachi, Junichi, Suzuki, Tomonari, Uchida, Eita, Nishikawa, Ryo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699117/ http://dx.doi.org/10.1093/noajnl/vdaa143.006

Ejemplares similares

ML-10 Tirabrutinib, a second-generation BTK inhibitor in relapsed and refractory primary CNS lymphoma: A single institute study
por: Mishima, Kazuhiko, et al.
Publicado: (2021)

PEDT-06 THERAPEUTIC STRATEGY FOR DISSEMINATED PILOCYTIC ASTROCYTOMAS
por: Suzuki, Tomonari, et al.
Publicado: (2019)

ML-08 THE ROLE OF MAINTENANCE HIGH-DOSE METHOTREXATE CHEMOTHERAPY IN ELDERLY PRIMARY CNS LYMPHOMA PATIENTS
por: Mishima, Kazuhiko, et al.
Publicado: (2019)

GEN-06 CLINICAL COURSE AFTER TUMOR RECURRENCE OF MGMT HYPERMETHYLATED GLIOBLASTOMA
por: Adachi, Junichi, et al.
Publicado: (2019)

ML-8 HIGH-DOSE CHEMOTHERAPY SUPPORTED BY AN AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED PRIMARY CNS LYMPHOMA
por: Mishima, Kazuhiko, et al.
Publicado: (2022)

Miliary Tuberculosis during R-MPV Therapy in an Elderly Patient with Primary Central Nerve System Lymphoma: A Case Report
por: Take, Yushiro, et al.
Publicado: (2023)

ML-05 One-year follow-up data of phase I/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
por: Mishima, Kazuhiko, et al.
Publicado: (2020)

TB-6 Experimental evaluation of the therapeutic potential of boron neutron capture therapy in primary central nervous system lymphoma
por: Yoshimura, Kohei, et al.
Publicado: (2021)

True anaplastic oligoastrocytoma with dual genotype: illustrative case
por: Mizuno, Reina, et al.
Publicado: (2022)

ML-3 A Case of Primary Central Nervous System Anaplastic Lymphoma Kinase Positive Anaplastic Large cell Lymphoma at Neurohypophysis and Pineal Gland
por: Kohno, Shohei, et al.
Publicado: (2021)

ML-23 The outcome of malignant lymphoma of the central nervous system in a single institution
por: Kuwahara, Kiyonori, et al.
Publicado: (2020)

COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
por: Onishi, Shumpei, et al.
Publicado: (2020)

ML-21 Tirabrutinib monotherapy for relapsed/refractory primary central nervous system lymphoma
por: Kobayashi, Keiichi, et al.
Publicado: (2020)

ML-01 Pathological characteristics of primary central nervous system lymphoma with atypical radiological finding
por: Inukai, Madoka, et al.
Publicado: (2020)

ML-15 The future direction of treatment development for primary central nervous system lymphoma (PCNSL)
por: Shinojima, Naoki, et al.
Publicado: (2020)

ML-08 Safety and efficacy of consolidation cytarabine for newly-diagnosed primary central nervous system lymphoma
por: Sasaki, Nobuyoshi, et al.
Publicado: (2020)

ML-18 Clinical diagnosis for suspected primary central nervous system lymphoma patients without histopathological confirmation
por: Osawa, Sho, et al.
Publicado: (2020)

ML-13 Primary central nervous system malignant lymphoma in a patient with rheumatoid arthritis receiving tocilizumab
por: Ohno, Masasuke, et al.
Publicado: (2021)

ML-20 Outcome of high-dose methotrexate-based chemotherapy with or without Rituximab for primary central nervous system lymphoma
por: Takezaki, Tatsuya, et al.
Publicado: (2020)

ML-04 The influence of surgical intervention for high-dose Methotrexate chemotherapy in the patients with primary central nervous system lymphoma
por: Okamoto, Michinari, et al.
Publicado: (2020)

ML-16 First clinical experience of administration of Tirabrutinib for the patients with newly diagnosed primary central nervous system lymphoma
por: Onodera, Sho, et al.
Publicado: (2021)

CBMS-04 Novel xenograft model to clarify tumor progressive mechanism and therapeutic target in primary central nervous system lymphoma
por: Tateishi, Kensuke, et al.
Publicado: (2020)

SS-2 Current status and future perspective of radiomics in glioma imaging
por: Kinoshita, Manabu, et al.
Publicado: (2020)

SS-4 High dose chemotherapy with autologous hematopoietic stem cell transplantation for CNS lymphoma
por: Kondo, Eisei
Publicado: (2020)

CBMS-11 PROTEIN DEUBIQUITINATION PATHWAY IS A NOVEL THERAPEUTIC TARGET AGAINST MALIGNANT CNS NON-GERMINOMATOUS GERM CELL TUMORS
por: Tomiyama, Arata, et al.
Publicado: (2020)

PEDT-5 Problem for the guideline of CNS germ cell tumors
por: Nakamura, Hideo, et al.
Publicado: (2021)

ET-05 Alectinib and ceritinib, the second-generation ALK inhibitors, effectively induce glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2020)

PEDT-02 DIAGNOSIS, TREATMENT AND CLINICAL OUTCOME OF ATYPICAL BRAINSTEM TUMOUR IN CHILDHOOD
por: Yanagisawa, Takaaki, et al.
Publicado: (2019)

A Case of Suspicious Gangliocytoma with Heterogeneously Distributed Lesions in the Thalamus and Basal Ganglia
por: Miyake, Yohei, et al.
Publicado: (2018)

SS-1 Therapeutic challenges for glioblastoma: Temozolomide and its issues?
por: Nagane, Motoo
Publicado: (2020)

SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine
por: Karschnia, Philipp, et al.
Publicado: (2021)

SS-3 Tumor Treating Fields: from the Petri dish to the patient
por: Giladi, Moshe
Publicado: (2020)

OTHR-04. Gynecological Malignancies With Metastasis To The Central Nervous System: A Case Series and Systematic Review of the Literature
por: Sajjad, Azeem, et al.
Publicado: (2021)

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
por: Narita, Yoshitaka, et al.
Publicado: (2020)

ML-9 TREATMENT OUTCOMES OF TIRABRUTINIB FOR RELAPSED AND REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN A SINGLE INSTITUTE
por: Ohka, Fumiharu, et al.
Publicado: (2022)

ML-18 High-dose chemotherapy supported by autologous stem cell transplant in relapsed and refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2021)

Immunotherapy of Nivolumab with Dendritic Cell Vaccination Is Effective against Intractable Recurrent Primary Central Nervous System Lymphoma: A Case Report
por: FURUSE, Motomasa, et al.
Publicado: (2017)

BOT-3 Prognostic Factors of CNS Germ Cell Tumors; Molecular and Histopathological Analyses on 154 Cases from the iGCT Consortium
por: Takami, Hirokazu, et al.
Publicado: (2021)

ACT-8 Current status and prospects for the treatment of malignant glioma using cancer gene panel tests
por: Koizumi, Shinichiro, et al.
Publicado: (2021)

ML-02 Chemotherapy for patients with relapsed or refractory primary CNS lymphoma
por: Nagane, Motoo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d9lljb0b91o92or0o61cvnrqp0